Table 5

Summary of ORR by PD-L1 status (safety analysis set)*†

Response category, n (%)NSCLC
(n=56)
Melanoma
(n=34)
ESCC
(n=26)
GC
(n=24)
UC
(n=22)
NPC
(n=21)
RCC
(n=21)
HCC
(n=18)
MSI-H/dMMR*
(n=16)
PD-L1-positive ORR, %170850050000
 n/N (%)24/56
(43)
4/34
(12)
13/26
(50)
4/24
(17)
4/22
(18)
16/21
(76)
2/21
(10)
01/16
(6)
 95% CI4.7 to 37.40.0 to 60.20.2 to 36.06.8 to 93.20.0 to 60.224.7 to 75.30.0 to 84.20.0 to 0.00.0 to 97.5
PD-L1-negative ORR, %19168121825111920
 n/N (%)31/56
(55)
25/34
(74)
13/26
(50)
17/24
(71)
17/22
(77)
4/21
(19)
18/21
(86)
16/18
(89)
10/16
(63)
 95% CI7.5 to 37.54.5 to 36.10.2 to 36.01.5 to 36.43.8 to 43.40.6 to 80.61.4 to 34.74.0 to 45.62.5 to 55.6
PD-L1 unknown ORR, %02000000020
 n/N (%)1/56
(2)
5/34
(15)
03/24
(13)
1/22
(5)
1/21
(5)
1/21
(5)
2/18
(11)
5/16
(31)
 95% CI0.0 to 97.50.5 to 71.60.0 to 0.00.0 to 70.80.0 to 97.50.0 to 97.50.0 to 97.50.0 to 84.20.5 to 71.6
  • *PD-L1 positivity was defined by ≥10% of tumor cells with PD-L1 membrane staining at any intensity.

  • †Percentages are based on the total number of patients in each subcategory.

  • dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; MSI-H, microsatellite instability-high; N/A, not applicable; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD-L1, programmed cell death ligand-1; RCC, renal cell carcinoma; UC, urothelial bladder cancer.